Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.

Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...

Meta-analysis of 64 clinical trials 'should give clinicians and their patients more confidence,' say Hopkins researchers ...

Twenty percent of potentially eligible youth are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs), with the ...

GLP-1 RAs appear to be helping people reduce medication use and limit trips to the emergency department for chronic migraine treatment.

A meta-analysis shows GLP-1 RA therapy does not significantly lower vascular dementia events compared with placebo in high-risk patient groups.

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy ...

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year ...

BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the ...

Research presented at AAAAI 2026 suggests GLP-1 RAs may provide clinical benefits for asthma management in patients with excess body weight.

RDX-002 resulted in 57% less weight regain after GLP-1 therapy, showing promise as a durable and well-tolerated weight management option.

Opportunities in the GLP-1 receptor agonist market include the development of new diabetes and obesity treatments with high efficacy, a growing product pipeline, and increasing R&D investments. Rising ...